SPRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. Despite very bullish Wall Street targets and a late-stage regulatory path (BLA timing in 1Q26 per analysts), the near-term setup leans bearish: today’s sharp drop (-3.31%) with price below the pivot (79.517) and pattern-based odds implying further downside over the next day/week/month. With no Intellectia buy signals active and no supportive near-term news flow, risk/reward is unattractive to chase immediately—better to wait for a clearer reversal or reclaim of key levels before considering entry.
Trend/structure: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been up, but price action is currently in a pullback phase. Momentum: MACD histogram is positive (0.675) but ‘positively contracting,’ indicating bullish momentum is fading. RSI(6) at ~40.9 is weak/neutral and not signaling an oversold bounce. Levels: Current price 77.625 is below Pivot 79.517 (near-term bearish). Key support S1 73.428 then S2 69.666; resistance R1 85.606 then R2 89.368. Bias: Near-term bearish-to-neutral until it reclaims the pivot and holds above ~79.5; otherwise the chart favors a drift toward 73–70 support.
Intellectia Proprietary Trading Signals
centered on tralesinidase alfa (TA-ERT) and potential for accelerated review.
on 2026-02-09 after hours could add volatility; company is still loss-making.
Latest quarter provided: 2025/Q3. Revenue fell to 0 (-100% YoY). Net loss widened slightly to -$8.212M (down -5.29% YoY). EPS -14.58 (down -7.43% YoY). Gross margin 0 (-100% YoY). Overall: still pre-commercial/clinical-stage economics with losses and no revenue; growth is currently driven more by pipeline milestones than operating results.
Recent trend: Ratings have gotten more bullish with upgrades/initiations and rising confidence into the 1Q26 BLA timeline. Leerink upgraded to Outperform ($160) after Breakthrough Therapy Designation and post-PIPE valuation reset; H.C. Wainwright initiated Buy ($220); Citizens JMP reiterated Outperform and nudged PT to $259. Wall Street pros: Late-stage asset (tralesinidase alfa), potential accelerated review, sizable peak-sales narratives. Wall Street cons: Valuation and price can swing sharply around financings (PIPE) and binary regulatory/clinical milestones; near-term fundamentals remain loss-heavy. Influential/political trading: No recent congress trading data available; hedge fund and insider activity described as neutral with no significant recent trends.
